Together, our results demonstrated that the expression of PRMT5 was highly increased in ovarian cancer and was associated with the overall survival of patients, suggesting that PRMT5 is a promising therapeutic target in ovarian cancer. This evidence concerns the gene PRMT5 and ovarian cancer.